119 related articles for article (PubMed ID: 2050302)
1. Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide.
Dunton CJ; Pfeifer SM; Braitman LE; Morgan MA; Carlson JA; Mikuta JJ
Gynecol Oncol; 1991 May; 41(2):113-6. PubMed ID: 2050302
[TBL] [Abstract][Full Text] [Related]
2. Prospective treatment of advanced or recurrent endometrial carcinoma with cisplatin, doxorubicin, and cyclophosphamide.
Burke TW; Stringer CA; Morris M; Freedman RS; Gershenson DM; Kavanagh JJ; Edwards CL
Gynecol Oncol; 1991 Mar; 40(3):264-7. PubMed ID: 2013451
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin-based chemotherapy regimen (DECAV) for uterine sarcomas.
Pautier P; Genestie C; Fizazi K; Morice P; Mottet C; Haie-Meder C; Le Cesne A; Lhommé C
Int J Gynecol Cancer; 2002; 12(6):749-54. PubMed ID: 12445254
[TBL] [Abstract][Full Text] [Related]
4. Treatment of advanced or recurrent endometrial adenocarcinoma with cyclophosphamide, doxorubicin, cis-Platinum, and megestrol acetate.
Lovecchio JL; Averette HE; Lichtinger M; Townsend PA; Girtanner RW; Fenton AN
Obstet Gynecol; 1984 Apr; 63(4):557-60. PubMed ID: 6538327
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced endometrial carcinoma.
Turbow MM; Ballon SC; Sikic BI; Koretz MM
Cancer Treat Rep; 1985 May; 69(5):465-7. PubMed ID: 4039978
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant chemotherapy with cisplatin, doxorubicin, and cyclophosphamide (PAC) for early-stage high-risk endometrial cancer: a preliminary analysis.
Stringer CA; Gershenson DM; Burke TW; Edwards CL; Gordon AN; Wharton JT
Gynecol Oncol; 1990 Sep; 38(3):305-8. PubMed ID: 2227540
[TBL] [Abstract][Full Text] [Related]
7. Treatment of advanced or recurrent adenocarcinoma of the endometrium with doxorubicin and cyclophosphamide.
Campora E; Vidali A; Mammoliti S; Ragni N; Conte PF
Eur J Gynaecol Oncol; 1990; 11(3):181-3. PubMed ID: 2209636
[TBL] [Abstract][Full Text] [Related]
8. Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide.
Chambers JT; Chambers SK; Kohorn EI; Carcangiu ML; Schwartz PE
Gynecol Oncol; 1996 Mar; 60(3):438-42. PubMed ID: 8774654
[TBL] [Abstract][Full Text] [Related]
9. Use of cisplatin, doxorubicin, and cyclophosphamide to treat advanced and recurrent adenocarcinoma of the endometrium.
Hancock KC; Freedman RS; Edwards CL; Rutledge FN
Cancer Treat Rep; 1986 Jun; 70(6):789-91. PubMed ID: 3731140
[TBL] [Abstract][Full Text] [Related]
10. Treatment of recurrent and metastatic endometrial cancer with cisplatin, doxorubicin, cyclophosphamide, and megestrol acetate.
Hoffman MS; Roberts WS; Cavanagh D; Praphat H; Solomon P; Lyman GH
Gynecol Oncol; 1989 Oct; 35(1):75-7. PubMed ID: 2477317
[TBL] [Abstract][Full Text] [Related]
11. Postoperative adjuvant chemotherapy with cisplatin, cyclophosphamide, and anthracycline (doxorubicin, epirubicin, pirarubicin) for endometrial cancer.
Yahata H; Hirakawa T; Fujita T; Ariyoshi K; Sonoda K; Amada S; Kobayashi H; Nakano H
Int J Clin Oncol; 2004 Aug; 9(4):317-21. PubMed ID: 15375709
[TBL] [Abstract][Full Text] [Related]
12. Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC).
Levenback C; Burke TW; Silva E; Morris M; Gershenson DM; Kavanagh JJ; Wharton JT
Gynecol Oncol; 1992 Sep; 46(3):317-21. PubMed ID: 1526508
[TBL] [Abstract][Full Text] [Related]
13. Multimodal treatment with doxorubicin, cisplatin, and ifosfamide for the treatment of advanced or metastatic uterine leiomyosarcoma: a unicentric experience.
Hadoux J; Rey A; Duvillard P; Lhommé C; Balleyguier C; Haie-Meder C; Morice P; Tazi Y; Leary A; Larue C; Pautier P
Int J Gynecol Cancer; 2015 Feb; 25(2):296-302. PubMed ID: 25581897
[TBL] [Abstract][Full Text] [Related]
14. Postoperative adjuvant cisplatin, doxorubicin, and cyclophosphamide (PAC) chemotherapy in women with high-risk endometrial carcinoma.
Burke TW; Gershenson DM; Morris M; Stringer CA; Levenback C; Tortolero-Luna G; Baker VV
Gynecol Oncol; 1994 Oct; 55(1):47-50. PubMed ID: 7959265
[TBL] [Abstract][Full Text] [Related]
15. Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Nagao S; Nishikawa T; Hanaoka T; Kurosaki A; Iwasa N; Hasegawa K; Fujiwara K
Jpn J Clin Oncol; 2014 Nov; 44(11):1040-4. PubMed ID: 25183770
[TBL] [Abstract][Full Text] [Related]
16. [Combination chemotherapy using cyclophosphamide, adriamycin, and cisplatin in recurrent or advanced endometrial cancer--a preliminary report].
Baba S; Kashimura M; Shinohara M; Kusano S; Sasayama T; Hamasaki K
Gan No Rinsho; 1989 Feb; 35(3):371-7. PubMed ID: 2926985
[TBL] [Abstract][Full Text] [Related]
17. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.
Conte PF; Bruzzone M; Chiara S; Sertoli MR; Daga MG; Rubagotti A; Conio A; Ruvolo M; Rosso R; Santi L
J Clin Oncol; 1986 Jun; 4(6):965-71. PubMed ID: 3519886
[TBL] [Abstract][Full Text] [Related]
18. Two sequential studies for primary peritoneal carcinoma: induction with weekly cisplatin followed by either cisplatin-doxorubicin-cyclophosphamide or paclitaxel-cisplatin.
Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
Gynecol Oncol; 1997 Nov; 67(2):141-6. PubMed ID: 9367697
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group.
Loehrer PJ; Kim K; Aisner SC; Livingston R; Einhorn LH; Johnson D; Blum R
J Clin Oncol; 1994 Jun; 12(6):1164-8. PubMed ID: 8201378
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma.
Smith MR; Peters WA; Drescher CW
Am J Obstet Gynecol; 1994 Jun; 170(6):1677-81; discussion 1681-2. PubMed ID: 8203425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
